Faculty Opinions recommendation of Mitochondrial fragmentation triggers ineffective hematopoiesis in myelodysplastic syndromes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740718272.793590674 ◽

2021 ◽

Author(s):

William Vainchenker

Keyword(s):

Myelodysplastic Syndromes ◽

Mitochondrial Fragmentation

Download Full-text

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes

Cancer Discovery ◽

10.1158/2159-8290.cd-21-0032 ◽

2021 ◽

pp. candisc.0032.2021

Author(s):

Yasushige Aoyagi ◽

Yoshihiro Hayashi ◽

Yuka Harada ◽

Kwangmin Choi ◽

Natsumi Matsunuma ◽

...

Keyword(s):

Myelodysplastic Syndromes ◽

Mitochondrial Fragmentation

Download Full-text

Neutrophil-specific reduction in the expression of granulocyte-macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes

British Journal of Haematology ◽

10.1046/j.1365-2141.2000.02398.x ◽

2000 ◽

Vol 111 (3) ◽

pp. 863-872 ◽

Author(s):

Yayoi Shikama ◽

Tsutomu Shichishima ◽

Hitoshi Ohto ◽

Paul T. Jubinsky ◽

Keyword(s):

Myelodysplastic Syndromes ◽

Colony Stimulating Factor ◽

Macrophage Colony Stimulating Factor ◽

Macrophage Colony ◽

Stimulating Factor

Download Full-text

Review for "Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial"

10.1002/hon.2755/v1/review1 ◽

2020 ◽

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Low Dose ◽

Download Full-text

Decision letter for "Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Frontline Azacytidine Treatment"

10.1002/hon.2710/v1/decision1 ◽

2019 ◽

Keyword(s):

Myelodysplastic Syndromes ◽

Pulmonary Infections

Download Full-text

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Myelodysplastic Syndromes, Date of authorisation: 17/12/2008, Revision: 18, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996bd ◽

2019 ◽

Author(s):

Keyword(s):

Myelodysplastic Syndromes ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Myelodysplastic Syndromes,Leukemia, Myelomonocytic, Chronic,Leukemia, Myeloid, Acute, Date of authorisation: 13/02/2020, Status: Authorised

Case Medical Research ◽

10.31525/cmr-29f3e7e ◽

2020 ◽

Author(s):

Keyword(s):

Myelodysplastic Syndromes ◽

Assessment Report ◽

Chronic Leukemia ◽

European Public ◽

European Public Assessment Report

Download Full-text

Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Case Medical Research ◽

10.31525/ct1-nct04139434 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Oral Administration ◽

Dose Escalation ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Chronic Myelomonocytic Leukemia ◽

Dose Escalation Study ◽

Myelomonocytic Leukemia ◽

Download Full-text

Faculty Opinions recommendation of TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.10045957.10797055 ◽

2011 ◽

Author(s):

Michael Williams

Keyword(s):

Disease Progression ◽

Myelodysplastic Syndromes ◽

Low Risk ◽

Tp53 Mutations ◽

Predict Disease Progression

Download Full-text

Faculty Opinions recommendation of Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1158168.626009 ◽

2009 ◽

Author(s):

Ron Paquette

Keyword(s):

Myelodysplastic Syndromes ◽

Conventional Care ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1161194.622576 ◽

2009 ◽

Author(s):

Elaine Sloand

Keyword(s):

High Risk ◽

Myelodysplastic Syndromes ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Study ◽

Download Full-text